Xeris Pharmaceuticals, Inc. (XERS): Price and Financial Metrics


Xeris Pharmaceuticals, Inc. (XERS): $1.63

-0.14 (-7.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

XERS POWR Grades


  • Value is the dimension where XERS ranks best; there it ranks ahead of 62.83% of US stocks.
  • The strongest trend for XERS is in Stability, which has been heading up over the past 179 days.
  • XERS's current lowest rank is in the Quality metric (where it is better than 2.76% of US stocks).

XERS Stock Summary

  • Xeris Biopharma Holdings Inc's stock had its IPO on June 21, 2018, making it an older stock than merely 13.06% of US equities in our set.
  • XERS's price/sales ratio is 7.52; that's higher than the P/S ratio of 80.68% of US stocks.
  • As for revenue growth, note that XERS's revenue has grown 142.67% over the past 12 months; that beats the revenue growth of 94.5% of US companies in our set.
  • Stocks that are quantitatively similar to XERS, based on their financial statements, market capitalization, and price volatility, are PWFL, BIOC, TELA, TRUE, and REFR.
  • Visit XERS's SEC page to see the company's official filings. To visit the company's web site, go to www.xerispharma.com.

XERS Valuation Summary

  • In comparison to the median Healthcare stock, XERS's price/earnings ratio is 106.03% lower, now standing at -2.2.
  • XERS's price/earnings ratio has moved up 12.3 over the prior 39 months.
  • Over the past 39 months, XERS's price/sales ratio has gone down 242.

Below are key valuation metrics over time for XERS.

Stock Date P/S P/B P/E EV/EBIT
XERS 2021-08-31 5.4 9.2 -2.2 -2.8
XERS 2021-08-30 5.4 9.2 -2.2 -2.8
XERS 2021-08-27 5.6 9.5 -2.2 -2.9
XERS 2021-08-26 5.6 9.5 -2.3 -2.9
XERS 2021-08-25 5.4 9.2 -2.2 -2.8
XERS 2021-08-24 5.3 8.9 -2.1 -2.7

XERS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XERS has a Quality Grade of D, ranking ahead of 9.9% of graded US stocks.
  • XERS's asset turnover comes in at 0.208 -- ranking 192nd of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows XERS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.208 0.661 -0.415
2021-03-31 0.162 0.651 -0.388
2020-12-31 0.134 0.544 -0.482
2020-09-30 0.107 0.504 -0.626
2020-06-30 0.046 0.218 -0.894
2020-03-31 0.035 0.204 -1.151

XERS Price Target

For more insight on analysts targets of XERS, see our XERS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 1.33 (Strong Buy)

XERS Stock Price Chart Interactive Chart >

Price chart for XERS

XERS Price/Volume Stats

Current price $1.63 52-week high $4.98
Prev. close $1.77 52-week low $1.25
Day low $1.63 Volume 16,304,300
Day high $1.77 Avg. volume 2,089,094
50-day MA $2.10 Dividend yield N/A
200-day MA $2.27 Market Cap 108.39M

Xeris Pharmaceuticals, Inc. (XERS) Company Bio


Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company’s preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.


XERS Latest News Stream


Event/Time News Detail
Loading, please wait...

XERS Latest Social Stream


Loading social stream, please wait...

View Full XERS Social Stream

Latest XERS News From Around the Web

Below are the latest news stories about Xeris Biopharma Holdings Inc that investors may wish to consider to help them evaluate XERS as an investment opportunity.

Leerink Partners Thinks Xeris Pharmaceuticals’ Stock is Going to Recover

In a report released today, Roanna Ruiz from Leerink Partners maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report), with a price target of $6.00. The company's shares closed last Tuesday at $2.57, close to its 52-week low of $1.77. According to TipRanks.com, Ruiz 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -34.1% and a 18.8% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Atea Pharmaceuticals, and Aligos Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xeris Pharmaceuticals with a $6.

Howard Kim on TipRanks | February 16, 2022

Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Paul R. Edick, Chairman and CEO of Xeris Biopharma, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 12:00pm Eastern Time. A live webcast of the fireside chat will be available o

Business Wire | February 9, 2022

Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

CHICAGO, January 31, 2022--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that Recorlev® (levoketoconazole) is now available for prescription. The U.S. Food and Drug Administration (FDA) approved Recorlev on December 31, 2021 for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surger

Yahoo | January 31, 2022

Mizuho Securities Thinks Xeris Pharmaceuticals’ Stock is Going to Recover

Mizuho Securities analyst Vamil Divan maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research Report) today and set a price target of $8.00. The company's shares closed last Friday at $2.22, close to its 52-week low of $1.77. According to TipRanks.com, Divan has 0 stars on 0-5 stars ranking scale with an average return of -3.9% and a 44.9% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals. Xeris Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $6.85.

Catie Powers on TipRanks | January 18, 2022

Xeris Biopharma Eyes High End Of FY21 Sales Outlook

Xeris Biopharma Holdings Inc (NASDAQ: XERS ) has reaffirmed its preliminary 2021 pro forma sales at a high-end of $76 million - $80 million guidance, approximately 55% growth from 2020. The company held year-end 2021 preliminary cash, cash equivalents, and investments of approximately $102 million. "2022 is off to a good Full story available on Benzinga.com

Benzinga | January 18, 2022

Read More 'XERS' Stories Here

XERS Price Returns

1-mo -18.50%
3-mo -42.40%
6-mo -32.37%
1-year -66.11%
3-year -84.65%
5-year N/A
YTD -44.37%
2021 -40.45%
2020 -30.21%
2019 -58.53%
2018 N/A
2017 N/A

Continue Researching XERS

Want to see what other sources are saying about Xeris Pharmaceuticals Inc's financials and stock price? Try the links below:

Xeris Pharmaceuticals Inc (XERS) Stock Price | Nasdaq
Xeris Pharmaceuticals Inc (XERS) Stock Quote, History and News - Yahoo Finance
Xeris Pharmaceuticals Inc (XERS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.573 seconds.